# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001628280-23-006972
**Filing Date:** 2023-3
**Character Count:** 66482
**Document Hash:** 005a8c577e005c048db7894344f11285
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-006972.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001628280-23-006972

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 43

**CONFORMED PERIOD OF REPORT**: 20230308

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ChromaDex Corp.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37752
- **FILM NUMBER:** 23716108

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

?xml version="1.0" ? cdxc-20230308

  

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 8, 2023** 

**CHROMADEX CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37752** | **26-2940963** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024**

(Address of principal executive offices, including zip code)

**(310) 388-6706**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDXC | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

------

**Item 2.02. &nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 8, 2023, ChromaDex Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, unless expressly incorporated by specific reference in such filing.

**Item 7.01. &nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On March 8, 2023, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.

The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, unless expressly incorporated by specific reference in such filing.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| [99.1](exhibit991-pressreleasexq4.htm) | [Press Release dated](exhibit991-pressreleasexq4.htm)March 8, 2023 |
| [99.2](cdxcearningspresentation.htm) | [Investor Presentation of ChromaDex Corporation](cdxcearningspresentation.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **CHROMADEX CORPORATION** | **CHROMADEX CORPORATION** |
| Dated: March 8, 2023 | By: | /s/ Brianna L. Gerber |
|  |  | Name: Brianna L. Gerber |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

![cdx_logoxhorizontal-lrg.jpg](cdx_logoxhorizontal-lrg.jpg)

**ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results**

*Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen.* 

**LOS ANGELES, CA - March 8, 2023 -** ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

&nbsp;&nbsp;&nbsp;&nbsp;

***Fourth Quarter 2022 and Recent Highlights***

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Total net sales were $21.0 million, up 18% from $17.8 million for the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Tru Niagen® net sales were $16.1 million, up 14% from $14.1 million for the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;• Selling and marketing expense as a percentage of net sales was 29.5% versus 48.7% in the prior year quarter, an improvement of 1,920 basis points.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Net loss was $1.4 million or $0.02 loss per share, an improvement of $0.06 per share from the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Adjusted EBITDA, a non-GAAP measure, was a profit of $0.4 million, a $3.8 million improvement from the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;• Signed long-term supply agreement with Nestlé Health Science, extending non-exclusive rights to sell Niagen® in multi-ingredient dietary supplements.

&nbsp;&nbsp;&nbsp;&nbsp;• Raised $7.7 million, net of offering costs, with Nestlé Health Science and existing strategic investors in October 2022.

&nbsp;&nbsp;&nbsp;&nbsp;• Granted two new U.S. patents, including one on NRH, which preclinical research suggests may be among the most potent and efficient of the NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline.

&nbsp;&nbsp;&nbsp;&nbsp;• Appointed Dr. Vilhelm Bohr, a leading aging and neurodegenerative disease researcher, to the Scientific Advisory Board.

&nbsp;&nbsp;&nbsp;&nbsp;• In December 2022, a clinical study published in the peer-reviewed journal *Aging Cell* finds that NR oral supplementation significantly increased NAD+ levels in the brain and positively impacted neurodegenerative biomarkers.

&nbsp;&nbsp;&nbsp;&nbsp;• In January 2023, a clinical study published in the peer-reviewed journal *Science Advances* finds that NR oral supplementation increased muscle mitochondrial biogenesis.

***Full Year 2022 Highlights***

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Delivered on latest financial outlook to investors across all metrics, and exceeded G&A outlook.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Total net sales of $72.0 million, up 7% from $67.4 million year over year.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Tru Niagen® net sales of $60.1 million, up 6% from $56.7 million year over year.

&nbsp;&nbsp;&nbsp;&nbsp;• Selling and marketing expense as a percentage of net sales improved 270 basis points year over year.

&nbsp;&nbsp;&nbsp;&nbsp;• General and administrative expense decreased $8.1 million year over year.

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Net loss was $16.5 million or $0.24 loss per share, an improvement of $0.16 per share year over year.

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA, a non-GAAP measure, was a loss of $10.0 million, an $8.9 million improvement year over year.

&nbsp;&nbsp;&nbsp;&nbsp;• Granted additional U.S. continuation patent to protect the novel manufacturing process of NR and its various salt forms, which now cover NR Chloride, NR Malate, and NR Tartrate salts through 2037. ChromaDex also holds two patents covering crystal forms of important intermediates in the production of NR Chloride, one of which was granted in 2022.

&nbsp;&nbsp;&nbsp;&nbsp;• Signed agreement with Sinopharm Xingsha, a subsidiary of one of China's largest pharmaceutical companies, to conduct cross-border sales of Tru Niagen® in Mainland China. Sinopharm Xingsha debuted Tru Niagen® at the China International Natural Health & Nutrition Expo (NHNE), a major trade show.

"ChromaDex proudly reported its best quarter ever, achieving $21.0 million in revenue in the fourth quarter, up 18% year-over-year and 23% sequentially," said Rob Fried, ChromaDex Chief Executive Officer. "We also achieved $0.4 million in Adjusted EBITDA, an important operational milestone as we reposition ChromaDex for growth with profitability in mind during these turbulent economic times. We end the year with $20.4 million in cash, no debt, some excellent new partners with Nestlé and Sinopharm and are poised for a great 2023."

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

***Results of operations for the three months ended December 31, 2022***

For the three months ended December 31, 2022 ("Q4 2022"), ChromaDex reported net sales of $21.0 million, an increase of $3.2 million, or 18%, compared to the fourth quarter of 2021 ("Q4 2021"). The increase in Q4 2022 revenues compared to Q4 2021 was driven by a $2.0 million increase in Tru Niagen® sales and $1.3 million higher Niagen® ingredient sales. Growth in Tru Niagen® sales was driven by higher sales to A.S. Watson, a related party, and a new partnership. Growth in Niagen® ingredient sales was due to an upfront minimum purchase commitment from Nestlé Health Science as part of the newly amended supply agreement.

Gross margin percentage declined by 400 basis points to 57.2% in Q4 2022 compared to 61.2% in Q4 2021. The decline in gross margin percentage is largely attributable to business mix and overall input cost and wage inflation.

Operating expense decreased $2.7 million to $13.5 million in Q4 2022, compared to $16.2 million in Q4 2021. Lower operating expense was largely due to a $2.4 million decrease in selling and marketing (S&M) expense paired with a $0.5 million decrease in general and administrative (G&A) expense which was partially offset by $0.2 million in higher research and development (R&D) expense. During Q4 2022, the Company continued to scale back selling and marketing expense to focus on the most efficient channels and investments, resulting in selling and marketing expense as a percentage of net sales of 29.5% compared to 48.7% in Q4 2021, an improvement of 1,920 basis points. The decline in general and administrative expense was primarily driven by a $0.4 million decrease in legal expense.

Net loss for Q4 2022 was $1.4 million or $0.02 loss per share compared to a net loss of $5.3 million or $0.08 loss per share for Q4 2021. Adjusted EBITDA, a non-GAAP measure, was a profit of $0.4 million for Q4 2022, a $3.8 million improvement from Q4 2021. See "Reconciliation of Non-GAAP Financial Measures" for a reconciliation of non-GAAP measures to net loss, the most directly comparable GAAP measure.

For Q4 2022, net cash outflow from operating activities was $0.3 million, compared to $4.9 million in Q4 2021 largely due to improvements in net loss of $3.9 million paired with changes in working capital.

***Results of operations for the year ended December 31, 2022***

For the full year ended December 31, 2022 ("FY 2022"), ChromaDex reported net sales of $72.0 million, up 7% compared to $67.4 million during the full year ended December 31, 2021 ("FY 2021"). The increase in FY 2022 revenues compared to FY 2021 was driven by growth in Tru Niagen® sales of $3.4 million, primarily from e-commerce, and $1.6 million higher Niagen® ingredient sales which were partially offset by a decrease in other ingredient sales of $0.3 million. Growth in Niagen® ingredient sales was due to an initial purchase commitment from Nestlé Health Science as part of the newly revised supply agreement.

Gross margin percentage declined by 210 basis points to 59.4% in FY 2022 compared to 61.5% in FY 2021. The decline in gross margin percentage is attributable to increases in supply chain headcount, including higher wages, and other inflationary pressures.

Operating expense decreased $7.1 million to $61.4 million in FY 2022, compared to $68.6 million in FY 2021. The decline in operating expense was largely due to $8.1 million in lower G&A expense which was partially offset by $1.0 million in higher R&D expense. The $8.1 million decline in G&A expense was primarily driven by lower legal expense of $9.9 million which was partially offset by higher severance and restructuring expense of $0.7 million paired with investments in technology, overall wage inflation and higher royalties expense. R&D expense increased due to increased headcount, share-based compensation expense and timing of projects.

Net loss for FY 2022 was $16.5 million or $0.24 loss per share compared to a net loss of $27.1 million or $0.40 loss per share for FY 2021. Adjusted EBITDA, a non-GAAP measure, was a loss of $10.0 million for FY 2022, an improvement of $8.9 million from FY 2021 primarily driven by improvements in net loss including lower legal expense and higher net sales. See "Reconciliation of Non-GAAP Financial Measures" for a reconciliation of non-GAAP measures to net loss, the most directly comparable GAAP measure.

For FY 2022, net cash outflow from operating activities was $15.1 million, compared to $24.2 million for FY 2021 due to improvements in net loss of $10.6 million partially offset by changes in working capital. ChromaDex ended FY 2022 with $20.4 million in cash and cash equivalents.

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**2023 Outlook**

Looking forward, for the full year, the Company expects at least 10% revenue growth, with a realistic possibility of significantly greater growth this year. The conservative end of the Company's outlook reflects prevailing macroeconomic uncertainty and only considers recurring, steady revenue growth from the e-commerce business and established partnerships. However, potential upside lies in new partnerships, channels, and products. The Company projects that gross margin will remain stable year over year as cost savings initiatives are expected to largely offset continued inflationary pressures. Moreover, further optimization, coupled with new and focused customer acquisition strategies are expected to result in reduced selling and marketing expense as a percentage of net sales. The Company plans to increase investments in research and development to drive future innovation and expects a reduction in general and administrative expense of $2 to $3 million year over year.

**Investor Conference Call**

A live webcast will be held Wednesday, March 8, 2023 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex's fourth quarter and fiscal year 2022 financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of ChromaDex's website at www.chromadex.com. The toll-free dial-in information for this call is 1-888-330-2446 with Conference ID: 4126168.

The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern time on March 8, 2023 to 11:59 p.m. Eastern time on March 14, 2023. The replay of the call can also be accessed by dialing 800-770-2030, using the Replay ID: 4126168.

**Important Note on Forward Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends" "estimates," "plans," "potential," "possible," "probable," "believes" "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from ChromaDex's Chief Executive Officer, and statements related to the Company's 2023 financial outlook including but not limited to revenue growth, gross margin, expenses, and investment plans.

Risks that contribute to the uncertain nature of the forward-looking statements include, but are not limited to, our relationships with major customers; our ability to maintain our sales, marketing, and distribution capabilities; a decline in general economic conditions nationally and internationally; inflationary conditions; the impact of the COVID-19 pandemic on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business; the market and size of the vitamin mineral and dietary supplement market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our reliance on of a limited number of third-party party suppliers for certain raw materials; inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions and capital raising transactions and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**About ChromaDex:**

ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio.

The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on Twitter @ChromaDex and Instagram @TruNiagen and subscribe to our latest news via our website accessible at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional updates and financial information about the Company.

**Contacts:** 

---

| | |
|:---|:---|
| **Investor Relations** | **Media Relations** |
| Thomas Shumaker | Kendall Knysch |
| LifeSci Advisors, Managing Director | Director of Media Relations |
| 1-917-929-7600 | 310-388-6706 ext. 689 |
| <u>tshumaker@lifesciadvisors.com</u> | <u>kendall.knysch@chromadex.com</u> |

---

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**ChromaDex Corporation and Subsidiaries**

 **Consolidated Statements of Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| *(In thousands, except per share data)* |  |  |  |  |
| Sales, net | $**20996** | $17759 | $**72050** | $67449 |
| Cost of sales | **8980** | 6891 | **29253** | 25959 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | **12016** | 10868 | **42797** | 41490 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | **6187** | 8641 | **28313** | 28352 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | **1279** | 1045 | **4826** | 3832 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | **5994** | 6498 | **28286** | 36379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **13460** | 16184 | **61425** | 68563 |
| Operating loss | **(1444)** | (5316) | **(18628)** | (27073) |
| Other income, net - Employee Retention Tax Credit | **—** |  | **2085** |  |
| Interest income (expense), net | **26** | (9) | **3** | (55) |
| Net loss | $**(1418)** | $**(5325)** | $**(16540)** | $**(27128)** |
| Basic and diluted loss per share attributable to common stockholders: | $**(0.02)** | $(0.08) | $**(0.24)** | $(0.40) |
| Basic and diluted weighted average common shares outstanding | **73878** | 68297 | **69729** | 67185 |

---

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**ChromaDex Corporation and Subsidiaries**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *(In thousands except par values, unless otherwise indicated)* | **2022** | **2021** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents, including restricted cash of $0.2 million for both periods presented | $**20441** | $28219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade receivables, net of allowances of $122 and $65, respectively; Including receivables from Related Party of $3.1 million and $2.1 million, respectively. | **8482** | 5226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | **14677** | 13601 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | **2967** | 1859 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **46567** | 48905 |
| Leasehold improvements and equipment, net | **2799** | 3003 |
| Intangible assets, net | **671** | 857 |
| Right-of-use assets | **3523** | 4352 |
| Other long-term assets | **497** | 723 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**54057** | $57840 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**9679** | $10423 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **7337** | 6481 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current maturities of operating lease obligations | **680** | 528 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current maturities of finance lease obligations | **16** | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer deposits | **157** | 161 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **17869** | 17613 |
| Deferred revenue | **3955** | 4346 |
| Operating lease obligations, less current maturities | **3539** | 4154 |
| Finance lease obligations, less current maturities | **22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | **25385** | 26113 |
| Commitments and Contingencies |  |  |
| **Equity** |  |  |
| ChromaDex Corporation and subsidiaries stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; authorized 150,000 shares; 74,567 shares and 68,126 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively. | **74** | 68 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **214094** | 200614 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | **(185493)** | (168953) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustments | **(3)** | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | **28672** | 31727 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $**54057** | $57840 |

---

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**ChromaDex Corporation and Subsidiaries**

**Unaudited Reconciliation of Non-GAAP Financial Measures**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Full Year 2022** |
| *(In thousands)* | **Q1 2022** | **Q2 2022** | **Q3 2022** | **Q4 2022** | **Full Year 2022** |
| Net loss, as reported | $(7740) | $(6397) | $(985) | $(1418) | $(16540) |
| &nbsp;&nbsp;&nbsp;*Adjustments:* |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense (income), net | 8 | 10 | 5 | (26) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 201 | 212 | 235 | 221 | 869 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 49 | 50 | 44 | 43 | 186 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right of use assets | 299 | 169 | 170 | 191 | 829 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 1888 | 1296 | 1229 | 1326 | 5739 |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance and restructuring | 821 | 17 | 181 | 13 | 1032 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income - Employee Retention Tax Credit |  |  | (2085) |  | (2085) |
| Adjusted EBITDA | $(4474) | $(4643) | $(1206) | $350 | $(9973) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** | **Reconciliation of Net Loss to Adjusted EBITDA** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Full Year 2021**  |
| *(In thousands)* | **Q1 2021** | **Q2 2021** | **Q3 2021** | **Q4 2021** | **Full Year 2021**  |
| Net loss, as reported | $(7381) | $(5566) | $(8856) | $(5325) | $(27128) |
| &nbsp;&nbsp;&nbsp;*Adjustments:* |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 19 | 12 | 15 | 9 | 55 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 221 | 226 | 232 | 211 | 890 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 60 | 61 | 53 | 51 | 225 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right of use assets | 126 | 128 | 131 | 126 | 511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 1284 | 1616 | 1822 | 1473 | 6195 |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance and restructuring | (10) | 13 | 342 | 6 | 351 |
| Adjusted EBITDA | $(5681) | $(3510) | $(6261) | $(3449) | $(18901) |

---

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

------

**Non-GAAP Financial Information:**

To supplement ChromaDex's unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. ChromaDex believes the presentation of such non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company's historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company's financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company's economic performance year-over-year.

Adjusted EBITDA is defined as net income before (a) interest, (b) depreciation, (c) amortization, (d) non-cash share-based compensation costs, (e) severance and restructuring expense and (f) Other income from the Employee Retention Tax Credit. While ChromaDex believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measures is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company's GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.

Non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company's non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

![cdx_logoxsymbolonly.jpg](cdx_logoxsymbolonly.jpg)&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 99.2

![](cdxcearningspresentation001.jpg)

ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC \| March 8, 2023

------

![](cdxcearningspresentation002.jpg)

2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2023 financial outlook, and which may be identified by the use of words like "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows (including achieving cash flow break-even), planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we recently offered and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management's current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities Exchange Commission (the "Commission"), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: our relationships with major customers; our ability to maintain our sales, marketing, and distribution capabilities; a decline in general economic conditions nationally and internationally; inflationary conditions; the impact of the COVID-19 pandemic on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business; the market and size of the vitamin mineral and dietary supplement market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our reliance on of a limited number of third-party party suppliers for certain raw materials; inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions and capital raising transactions and other factors relating to our industry, our operations and results of operations. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. About Non-GAAP Financial Measures ChromaDex's non-GAAP financial measure, Adjusted EBITDA is defined as net income before interest, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense and other income from the Employee Retention Tax Credit. ChromaDex used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for ChromaDex's financial results in accordance with GAAP. Reconciliation of this non-GAAP measures to the most directly comparable GAAP measure is attached to this presentation. FDA Disclaimer Statements made in this presentation have not been evaluated by the Food and Drug Administration. ChromaDex products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors. SAFE HARBOR STATEMENT

------

![](cdxcearningspresentation003.jpg)

3 Q4 2022 & Recent Highlights (1) See slide 12 for the non-GAAP reconciliation Delivered on business and financial objectives, with an emphasis on bottom line in the current macroeconomic environment. In 2023, expect to make investments in targeted brand building initiatives and R&D to drive future innovation, while continuing to optimize our operations. • Total company and Tru Niagen® net sales were up 18% and 14% YoY, respectively. • Delivered on all full year 2022 financial outlook across all metrics, and achieved positive Adjusted EBITDA in the fourth quarter. • Net loss was $1.4 million or $0.02 loss per share, compared to a net loss of $5.3 million or $0.08 loss per share, in Q4 2021. • Underlying business, as measured by Adjusted EBITDA(1), delivered a profit of $0.4 million, a $3.8 million improvement, compared to a loss of $3.4 million in Q4 2021. • Selling and marketing expense as a percentage of net sales was 29.5% versus 48.7% in the prior year quarter, an improvement of 1,920 basis points from Q4 2021, reflecting optimized spending across the organization. • Delivered a $2.7 million reduction in operating expense from Q4 2021 and gross margin of 57.2%, which was impacted by business mix, as well as overall supply chain cost inflation, partially offset by cost savings initiatives. • Ended the quarter with $20.4 million in cash. Raised $7.7 million, net of offering costs, with Nestlé Health Science and existing strategic investors in October 2022. • Granted two new U.S. patents, including one on NRH, which preclinical research suggests may be among the most potent and efficient of the NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline. • Continued emphasis on efficiency as we pursue growth opportunities in 2023, while making strategic investments in brand building and R&D to drive long-term revenue growth and remain a leader in the NAD+ market.

------

![](cdxcearningspresentation004.jpg)

4 Management Team Rob Fried Chief Executive Officer E-commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Fadi Karam Chief Marketing Officer Former Nestlé executive Deep brand building experience, across traditional retail as well as E-commerce platforms Brianna Gerber Chief Financial Officer Over 20 years of diverse experience in investment management and finance at the Capital Group, Mattel, and ChromaDex Heather Van Blarcom SVP, Legal & Corporate Secretary Over two decades of industry experience with extensive knowledge of FDA and FTC regulations Andrew Shao SVP, Global Regulatory & Scientific Affairs Over two decades of global nutrition industry experience at Amway, Herbalife Nutrition, and the Council for Responsible Nutrition.

------

![](cdxcearningspresentation005.jpg)

5 Financial Highlights

------

![](cdxcearningspresentation006.jpg)

6 Q4 2022 Net Sales Mix E-commerce 63% Watson's & Other B2B 17% Niagen® Ingredient 14% Analytical Reference Standards & Services 5% Other Ingredients 1% $17.8 MM Q4 2021Q4 2022 • Tru Niagen® net sales decreased to 77% of net sales in Q4 2022 compared to 80% in Q4 2021(1) • Niagen®-related net sales increased to 96% of net sales in Q4 2022 compared to 94% in Q4 2021(2) E-commerce 53% Watson's & Other B2B 24% Niagen® Ingredient 19% Analytical Reference Standards & Services 4% Other Ingredients 0% $21.0 MM Higher mix of Watson's and Other B2B sales due to a catch-up in shipments for Watson's, and higher mix of Niagen® ingredient sales driven by Nestlé upfront minimum purchase. (1) Tru Niagen® net sales include E-commerce, Watson's/Other B2B (2) Niagen®-related sales include Tru Niagen® and Niagen® ingredient

------

![](cdxcearningspresentation007.jpg)

7 Q4 2022 Net Sales Q4 2022 Net Sales ($ in millions) $16.1 11.1 5.0 3.9 0.9 0.1 E-commerce Watson's & Other B2B Niagen® Ingredient Analytical Reference Standards & Services Other Ingredients Total net sales up 18% year-over-year and 23% sequentially driven by growth in Watson's / Other B2B and Niagen® ingredient. Growth Rates YoY % (vs Q4 2021) QoQ % (vs Q3 2022) —% (2)% +67% +49% +53% +110% +2% +28% (46)% +221% +18% +23%Total

------

![](cdxcearningspresentation008.jpg)

8 Full Year 2022 Net Sales FY 2022 Net Sales ($ in millions) Total +7% +8% —% +24% (6)% (31)% YoY % (vs FY 2021) $60.1 45.3 14.8 8.3 3.2 0.4 E-commerce Watson's & Other B2B Niagen® Ingredient Analytical Reference Standards & Services Other Ingredients Strong growth in Tru Niagen® from E-commerce, paired with growth in Niagen® ingredient sales, partially offset by lower other ingredient sales.

------

![](cdxcearningspresentation009.jpg)

9 2020 – 2022 Net Sales Summary (in millions) 2020 2021 2022 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY E-commerce 8.2 8.1 8.7 9.5 34.5 9.6 10.6 10.5 11.1 41.8 10.9 12.0 11.3 11.1 45.3 Watson's 1.8 1.3 2.5 2.1 7.6 1.6 2.9 2.6 2.2 9.3 2.6 1.5 2.6 3.3 10.0 Other B2B 1.1 2.3 0.8 0.8 5.0 1.3 1.8 1.6 0.8 5.6 1.4 1.0 0.7 1.7 4.8 Total TRU NIAGEN 11.1 11.7 11.9 12.3 47.1 12.4 15.4 14.8 14.1 56.7 14.9 14.5 14.6 16.1 60.1 NIAGEN Ingredient 2.0 2.0 0.9 2.2 7.1 1.2 1.3 1.7 2.5 6.7 1.1 1.5 1.8 3.9 8.3 NIAGEN Related Revenues 13.1 13.7 12.8 14.6 54.2 13.6 16.7 16.4 16.6 63.4 16.0 16.0 16.4 20.0 68.4 Other Ingredients 0.5 0.9 0.6 0.1 2.1 0.1 0.2 0.1 0.2 0.7 0.3 0.0 0.0 0.1 0.4 Analytical Reference Standards & Services 0.7 0.7 0.8 0.8 3.0 0.9 0.8 0.8 0.9 3.4 0.9 0.7 0.7 0.9 3.2 Total Net Sales 14.3 15.3 14.2 15.4 59.3 14.7 17.7 17.3 17.8 67.4 17.2 16.7 17.1 21.0 72.0 TRU NIAGEN as % of Total Net Sales 78 % 77 % 84 % 80 % 79 % 85 % 87 % 85 % 80 % 84 % 86 % 87 % 85 % 77 % 84 % NIAGEN Related Revenues as % of Total Net Sales 91 % 90 % 90 % 94 % 91 % 93 % 94 % 95 % 94 % 94 % 93 % 95 % 96 % 96 % 95 % YOY Growth Rate - Net Sales Total Company 43 % 38 % 18 % 18 % 28 % 2 % 16 % 22 % 15 % 14 % 18 % (5) % (1) % 19 % 7 % NIAGEN Related 53 % 40 % 22 % 20 % 32 % 4 % 22 % 29 % 14 % 17 % 18 % (4) % (1) % 20 % 8 % Total TRU NIAGEN 50 % 34 % 22 % 21 % 31 % 12 % 31 % 24 % 14 % 20 % 20 % (6) % (1) % 14 % 6 % Sequential Growth Rate - Net Sales Total Company 10 % 7 % (7) % 9 % (5) % 21 % (2) % 3 % (3) % (3) % 2 % 23 % NIAGEN Related 8 % 5 % (7) % 14 % (6) % 22 % (1) % 1 % (4) % (1) % 2 % 22 % Total TRU NIAGEN 10 % 5 % 2 % 4 % 1 % 24 % (4) % (5) % 6 % (3) % — % 11 %

------

![](cdxcearningspresentation010.jpg)

10 Q4 2022 vs Q3 2022 Key P&L Metrics (in thousands) Q4 2022 Q3 2022 Notes Net Sales $20,996 $17,063 Tru Niagen® business up 11% and increased Niagen® ingredient sales driven by upfront purchase from Nestlé of $2.0MM. Gross Profit % of Net Sales 12,016 57.2% 10,207 59.8% Gross margin down mainly due to business mix and overall cost inflation, partially offset by cost savings initiatives and scale. Selling and Marketing % of Net Sales 6,187 29.5% 5,868 34.4% Improvements as a percentage of sales reflects focus on most efficient direct-response E-commerce channel and highest return digital investments, as well as overall scale. Research and Development 1,279 1,224 Up slightly with focused strategic investments and headcount to support R&D innovation pipeline. General and Administrative 5,994 6,180 Excluding legal fees, severance & restructuring, and equity compensation expense, G&A was down by $(0.1) million. Total Operating Expense 13,460 13,272 Lower G&A expense offset by increased investments in selling and marketing. Operating Loss $(1,444) $(3,065) Higher sales and relatively flat overall operating expense.

------

![](cdxcearningspresentation011.jpg)

11 Q4 2022 vs Q4 2021 Key P&L Metrics (in thousands) Q4 2022 Q4 2021 Notes Net Sales $20,996 $17,759 Tru Niagen® business up 14% driven by increased sales to partners, including a catch-up in shipments to Watson's. Niagen® ingredient sales up 53% year-over-year. Gross Profit % of Net Sales 12,016 57.2% 10,868 61.2% Down (400) bps driven by business mix and overall input cost and wage inflation. Selling and Marketing % of Net Sales 6,187 29.5% 8,641 48.7% Improvements reflect focus on most efficient direct-response E- commerce channel and highest return digital investments. Research and Development 1,279 1,045 Up year-over-year with focused strategic investments and headcount to support R&D innovation pipeline. General and Administrative 5,994 6,498 Excluding legal fees, severance & restructuring, and equity compensation expense, G&A was up by $0.1 million. Total Operating Expense 13,460 16,184 Lower selling and marketing expense, lower G&A expense driven by reduced litigation expense, marginally offset by higher R&D expense. Operating Loss $(1,444) $(5,316) Higher sales paired with lower overall operating expense.

------

![](cdxcearningspresentation012.jpg)

12 Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Net loss, as reported $(5,902) $(3,711) $(4,215) $(6,097) $(7,381) $(5,566) $(8,856) $(5,325) $(7,740) $(6,397) $(985) $(1,418) Adjustments Interest (income) expense 12 24 19 16 19 12 15 9 8 10 5 (26) Depreciation 214 218 220 219 221 226 232 211 201 212 235 221 Amortization of intangibles 62 60 60 61 60 61 53 51 49 50 44 43 Amortization of right of use assets 92 95 97 115 126 128 131 126 299 169 170 191 Share-based compensation 1,873 1,711 1,574 1,778 1,284 1,616 1,822 1,473 1,888 1,296 1,229 1,326 Severance and restructuring 953 284 224 329 (10) 13 342 6 821 17 181 13 Other income - Employee Retention Tax — — — — — — — — — — (2,085) — Adjusted EBITDA $(2,696) $(1,319) $(2,021) $(3,579) $(5,681) $(3,510) $(6,261) $(3,449) $(4,474) $(4,643) $(1,206) $350 Q4 2022 Adjusted EBITDA was a profit of $0.4 million, compared to a loss of $(3.4) million in the prior year quarter driven by higher sales and lower operating expense, and an improvement of $1.6 million sequentially.

------

![](cdxcearningspresentation013.jpg)

13 Q4 2022 Operating Loss vs Q4 2021 (5.3) 2.4 2.0 0.4 0.2 (0.1) (0.2) (0.8) (1.4) Q4 2021 Operating Loss Sales & Marketing Volume Legal Equity Comp (G+A) Other G+A Research & Development Gross Margin Decline Q4 2022 Operating Loss (6.0) (5.0) (4.0) (3.0) (2.0) (1.0) — (in millions) +$5.0MM $(1.1) MM

------

![](cdxcearningspresentation014.jpg)

14 Quarterly Balance Sheet Highlights Invested in future growth, continued to manage working capital. Raised $7.7 million, net of offering costs, in October 2022. (in thousands) 12/31/20 3/31/21 6/30/21 9/30/21 12/31/21 3/31/22 6/30/22 9/30/22 12/31/22 Key Drivers (FY 2022 vs 2021) Cash $16,697 $44,691 $38,778 $33,102 $28,219 $20,993 $17,072 $13,262 $20,441 Cash used from operations to scale the business, offset by $7.7 million capital raise Inventory 11,683 12,762 12,183 12,676 13,601 15,307 15,753 15,636 14,677 Investments to support growth Trade Receivables 2,694 4,647 5,999 5,295 5,226 6,310 4,228 4,744 8,482 Driven by mix of customer sales and timing of collections, including $2.0MM Nestle upfront purchase Accrued Liabilities 6,133 7,328 5,569 6,331 6,481 8,126 6,696 6,756 7,337 Driven by changes in expenses and accrual for employee bonuses Accounts Payable 9,445 11,693 9,970 10,804 10,423 9,780 10,197 9,119 9,679 Driven by changes in inventory, advertising and legal expense Equity $16,424 $43,832 $42,142 $35,449 $31,727 $25,877 $20,778 $21,023 $28,672 Driven by $7.7 million capital raise

------

![](cdxcearningspresentation015.jpg)

15 Quarterly Cash Flow Highlights (in thousands) FY 2020 3/31/21 6/30/21 9/30/21 12/31/21 FY 2021 3/31/22 6/30/22 9/30/22 12/31/2022 FY 2022 Net Loss $(19,925) $(7,381) $(5,566) $(8,856) $(5,325) $(27,128) $(7,740) $(6,397) $(985)(3) $(1,418) $(16,540) Working Capital 383 258 (4,390) 942 (1,670) (4,915) (1,923) 923 (4,461)(3) (466) (5,927) Cash Used for Operations (10,600) (5,405) (7,895) (5,919) (4,944) (24,163) (7,198) (3,832) (3,740) (328) (15,098) Cash Used for Investing (165) (46) (265) (96) (2) (409) (25) (85) (52) (172) (334) Cash From / (Used for) Financing 8,650 33,445(1) 2,247(2) 339 63 36,094 (3) (4) (18) 7,679(4) 7,654 Net Increase / (Decrease) in Cash $(2,115) $27,994 $(5,913) $(5,676) $(4,883) $11,522 $(7,226) $(3,921) $(3,810) $7,179 $(7,778) Ending Cash Balance $16,697 $44,691 $38,778 $33,102 $28,219 $28,219 $20,993 $17,072 $13,262 $20,441 $20,441 1. Includes $25 million issuance of common stock, net of $129,000 of issuance costs, and includes $8.6 million proceeds from exercise of stock options. 2. Includes $2.2 million issuance of common stock, net of $299,000 of issuance costs, and include $0.4 million proceeds from exercise of stock options. 3. Includes $2.1 million related to the Employee Retention Tax Credit (no net cash flow impact). 4. Includes $7.7 million issuance of common stock, net of $353,000 of issuance costs. Investments to grow the business and protect our IP, while managing working capital

------

![](cdxcearningspresentation016.jpg)

16 2022 Full Year Outlook Recap (in thousands) 2021 Actual 2022 Outlook (1) 2022 Actual Comments Achieved?(2) Net Sales $67,449 High single digits growth YoY $72,050 Total net sales grew by +7% and Tru Niagen® net sales grew by +6% year- over-year ü Gross Margin % (as a % of net sales) 61.5% Approximately 60% 59.4% Reflects strength of business model, navigating significant cost inflation ü Selling, Marketing & Advertising (as a % of net sales) 42.0% Down as a % of net sales 39.3% Down (270) bps as a % of net sales year-over-year ü Research & Development $3,832 Up approximately $1 million $4,826 Up $1.0 million year-over-year ü General & Administrative $36,379 Down $6 to $8 million $28,286 Down $(8.1) million year-over-year ü Adjusted EBITDA $(18,901) Outlook not provided $(9,973) Improvement of $8.9 million year-over- year reflecting higher sales and lower overall operating expense N/A Company delivered on its latest financial outlook across all metrics and exceeded target for G&A expense reduction. (1) 2022 Outlook as presented on Q2 2022 earnings call, except for G&A. 2022 Outlook for G&A updated on Q3 2022 earnings call, previous outlook was "G&A Down $6-7MM". (2) Compares 2022 actuals to 2022 Outlook.

------

![](cdxcearningspresentation017.jpg)

17 2023 Financial Outlook (in thousands) 2021 Actual 2022 Actual 2023 Full Year Outlook Key Drivers Net Sales $67,449 $72,050 At least 10% growth YoY, with realistic possibility of significantly greater growth • Low-end includes steady growth from E- commerce business & recurring revenues from established partnerships; • Upside from new partnerships, channels, and products Gross Margin % (as a % of net sales) 61.5% 59.4% Stable YoY • Cost savings initiatives and scale offsetting continued inflationary pressures Selling, Marketing & Advertising (as a % of net sales) 42.0% 39.3% Down as a % of net sales • Focused and optimized investments to drive Tru Niagen® brand awareness; • Larger brand campaign in Q1 2023 Research & Development $3,832 $4,826 Up in absolute dollars YoY • Increased investment in future innovation, including new NAD precursor development General & Administrative $36,379 $28,286 Down $2 to $3 million • Reduction in severance, share-based compensation, and other general expenses Continued solid revenue growth in 2023, and further optimization of cost structure, with selective investments in larger brand building initiatives and R&D to drive future innovation.

------

![](cdxcearningspresentation018.jpg)

18 Adjusted EBITDA 2022 vs 2021 ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Year Ended Year-over-Year ChangeDec 31, 2021 Dec 31, 2022 Net loss, as reported $(27,128) $(16,540) $10,588 Adjustments Interest (income) expense 55 (3) (58) Depreciation 890 869 (21) Amortization of intangibles 225 186 (39) Amortization of right of use assets 511 829 318 Share-based compensation 6,195 5,739 (456) Severance and restructuring 351 1,032 681 Other income - Employee Retention Tax Credit — (2,085) (2,085) Adjusted EBITDA $(18,901) $(9,973) $8,928 2022 Adjusted EBITDA was a loss of $(10.0) million, an improvement of $8.9 million, compared to a loss of $(18.9) million in the prior year primarily driven by higher sales and lower operating expenses. (1) The Company has decided to discontinue reporting Adjusted EBITDA excluding legal expense. However, for informational purposes, during the years ended December 31, 2022 and 2021 total legal expense was $6,539 and $16,426.

------

![](cdxcearningspresentation019.jpg)

19 Q4 2022 Financial Highlights - Recap • Total net sales of $21.0 million in Q4 2022 (+18% YoY, +23% versus Q3 2022). • Continued progress building Tru Niagen® into a global brand. ◦ Tru Niagen® net sales of $16.1 million in Q4 2022 (+14% YoY, +11% vs Q3 2022). • Solid gross margin of 57.2% ((400) bps YoY, (260) bps vs Q3 2022). ◦ Gross margin of 57.2% in Q4 2022 vs 61.2% in Q4 2021 and 59.8% in Q3 2022. ◦ Declines are primarily driven by business mix, as well as overall input cost and wage inflation. • Marketing efficiency driven by focus on investments with measurable return ((1,920) bps YoY, (490) bps versus Q3 2022). ◦ Selling and marketing expense was 29.5% of net sales in Q4 2022 compared to 48.7% in Q4 2021 and 34.4% in Q3 2022. ◦ Pivoted our focus to the most efficient, direct response E-commerce channel. • General and administrative expense (G&A) was $6.0 million, down $(0.5) million YoY and $(0.2) million sequentially. ◦ Declines largely driven by lower legal expense YoY and lower severance and restructuring expense sequentially. • Net loss was $1.4 million or $0.02 loss per share, compared to a net loss of $5.3 million or $0.08 loss per share in Q4 2021. • Adjusted EBITDA was a profit of $0.4 million compared to a loss of $3.4 million in Q4 2021, a $3.8 million improvement YoY. Delivered a solid fourth quarter, both top- and bottom-line and continued to demonstrate financial discipline with lower overall spend, while making important investments to build our Tru Niagen® brand and drive R&D innovation.

------

![](cdxcearningspresentation020.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) The Science 20

------

![](cdxcearningspresentation021.jpg)

21 • Five new human trials on nicotinamide riboside registered since prior update:¹ ▪ Haukeland University Hospital (November 2022) • The objective is to determine the optimal dose of NR in individuals with Alzheimer's disease (AD) • Three key questions the trial is aiming to answer are: ▪ What dose of NR is required to achieve maximal increase in cerebral NAD+? ▪ What dose of NR is required to achieve maximal alteration in cerebral metabolism patterns? ▪ What dose of NR will have an optimal effect with no toxic effects? • 80 participants will receive either 1,000mg or escalating doses of NR (1,000mg to 2,000 mg to 3,000mg) daily for 12 weeks ▪ Haukeland University Hospital (January 2023) ▪ The objective is to determine the blood and brain pharmacokinetics of NAD replenishment therapy (NRT) using NR or nicotinamide mononucleotide (NMN) ▪ The study will consist of two 20-day periods, each of which will start with 8 days of daily intake of NR or NMN. The two 20-day periods will be 14 days apart to allow for elimination from the body of the previous compound ▪ 6 participants will receive 1,200mg NR or 1,200mg NMN daily for 8 days and then enter an elimination period of 14 days ▪ University Hospital, Akershus (January 2023) ▪ The primary objective is to determine whether daily NR supplementation and/or Mind-Body Reprocessing Therapy (MBRT) can increase health-related quality of life in individuals with Long COVID compared with standard care and/or placebo ▪ The MBRT consists of 4 to 6 face-to-face therapist encounters in combination with digital resources ▪ Standard care consists of a brief self-help leaflet on long COVID, otherwise care as usual by the general practitioner ▪ 310 participants will receive either MBRT and 2,000mg NR daily, MBRT and placebo, standard care and 2,000mg NR daily, or standard care and placebo (1) There are 83 ongoing, completed, and published clinical studies currently registered on clinicaltrials.gov to investigate the pharmacokinetics and therapeutic effects of NR alone or in combination with other ingredients. 67 of these use NR only. Clinicaltrials.gov also includes two niacin studies and one device monitoring registry for a total of 86 under the search term "nicotinamide riboside." (As of February 23, 2023) Science Continues to Expand

------

![](cdxcearningspresentation022.jpg)

22 • University Hospital, Akershus (February 2023) • The objective is to determine whether NR can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline chemotherapy • Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival; however, they have simultaneously increased the risk for cardiotoxicity and development of heart failure • 60 participants will receive 1,000mg NR daily for 3-6 months depending on anthracycline therapy duration • Haukeland University Hospital (February 2023) • The objective is to assess the safety and efficacy of NR for the treatment of patients with progressive multiple sclerosis • The primary question the trial is aiming to answer is: Does NR delay disability progression in progressive multiple sclerosis? • 300 participants will receive 1,000mg NR daily for 30 months • Six new research studies signed through ChromaDex External Research Program (CERP)² (2) 250+ research collaborations for Niagen® signed with research institutes and universities around the world. More than 90% of the studies are investigator initiated and were developed to support applications for or receipt of third-party funding. The studies may not have been initiated if investigators were unable to secure funding. Science Continues to Expand (continued)

------

![](cdxcearningspresentation023.jpg)

23 • Aging Cell – Vreones et al., 2022 – "Oral Nicotinamide Riboside Raises NAD+ and Lowers Biomarkers of Neurodegenerative Pathology in Plasma Extracellular Vesicles Enriched for Neuronal Origin." – December 2022 • The study investigated whether NR could positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma. • NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma. They can contain RNA, DNA, and/or proteins that provide information relating to the metabolism of their tissue of origin, and serve as signaling molecules between various cells, tissues, or organs. • NR supplementation significantly increased NAD+ in NEVs, suggesting an increase in neuronal NAD+ levels. • In those with an increase in NAD+, NR supplementation also decreased NEV levels of Aβ42, an Alzheimer's disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways. • The results of this study are consistent with previous clinical research demonstrating NR can increase brain NAD+ levels (Brakedal et al., 2022). • Science Advances – Lapatto et al., 2023 – "Nicotinamide Riboside Improves Muscle Mitochondrial Biogenesis, Satellite Cell Differentiation, and Gut Microbiota in a Twin Study." – January 2023 • The study investigated the effects of long-term (five months) NR supplementation on mitochondrial biogenesis and metabolic health in BMI-discordant (one leaner, one heavier) identical twin pairs. • NR also increased muscle mitochondrial biogenesis, increasing the number and density of muscle mitochondria, and improved gut microbiota composition, as seen through an increase in the abundance of Faecalibacterium prausnitzii—one of the most beneficial bacteria found in the microbiome of healthy humans. • This is the first published and peer-reviewed clinical study demonstrating an increase in mitochondrial biogenesis and the longest published NR supplementation study to date. Recent Peer-Reviewed Clinical Publications

------

![](cdxcearningspresentation024.jpg)

24 Recent Peer-Reviewed Clinical Publications • Translational Neurodegeneration – Yulug et al., 2023 – "Combined Metabolic Activators Improve Cognitive Functions in Alzheimer's Disease Patients: A Randomized, Double-Blinded, Placebo-Controlled Phase-II Trial." – January 2023 • The study investigated a combined metabolic activator (CMA), or ingredient 'cocktail', featuring NR, in addition to L-carnitine tartrate, serine, and N-acetyl-L-cysteine (NAC) in mild-to-moderate patients with Alzheimer's disease (AD). • CMA safely and significantly improved cognitive function by 29% (vs. placebo which improved only 14%) compared to baseline, according to the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), a standardized tool used to assess the severity of cognitive symptoms in AD patients. • CMA appeared to have the greatest benefit on ADAS-Cog in those patients with more advanced AD. • CMA significantly improved serum biomarkers related to AD, as well as markers of liver and kidney health. • This is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.

------

![](cdxcearningspresentation025.jpg)

25 Scientific Advisory Board Charles Brenner, Ph.D. Alfred E Mann Family Foundation Chair, Department of Diabetes & Cancer Metabolism City of Hope World's Foremost Authority on NAD Metabolism Roger Kornberg, Ph.D. Chairman Professor of Structural Biology Stanford University Nobel Prize Winner, Chemistry, 2006 Rudolph Tanzi, Ph.D. Kennedy Professor of Neurology Harvard University Leading Alzheimer's Researcher, TIME 100 Most Influential 2015 Dr. Bruce German Chairman of Food, Nutrition, & Health University of California, Davis Leader in Food, Nutrition, & Wellness Innovation Professor Sir John Walker, Ph.D. Emeritus Director, MRC Mitochondrial Biology University of Cambridge Nobel Prize Winner, Chemistry, 1997 Brunie H. Felding, Ph.D. Associate Professor of Molecular Medicine Scripps Research Institute Renowned Breast Cancer Researcher focused on NAD+ supplementation Dr. David Katz President of True Health Initiative CEO of Diet ID World renowned physician & preventive medicine expert Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. Professor in Genome Instability and Neurodegeneration, Department of Cellular and Molecular Medicine, University of Copenhagen. One of the world's most published researchers on aging and neurodegenerative disease NOBEL PRIZE WINNERS \| CHEMISTRY

------

![](cdxcearningspresentation026.jpg)

26 Basic Physiological Functions are NAD+ Dependent INTRINSIC CAPACITY DOMAIN Based on World Health Organization's definition VITALITY Energy metabolism Hormonal function Cardio-respiratory function Number of clinical trials (active)\* 15 Number of clinical trials (complete)\* 9 % of all registered Niagen® clinical trials\*\* 46% Type II Diabetes (Insulin Sensitivity) Altered Glucose and Lipid Metabolism Non-Alcoholic Fatty Liver Heart Failure Hypertension Arterial Stiffness Vascular Function Immunity/Inflammation Chronic Kidney Disease Conditions Studied LOCOMOTION Muscle strength Balance Gait 9 6 Parkinson's Disease Ataxia Telangiectasia Exercise Capacity/ Performance Muscle Function/Strength Sarcopenia COGNITION Memory Intelligence Problem-solving 2 5 13% Mild Concussion Mild Cognitive Impairment Alzheimer's Disease SENSORY Vision Hearing 4 0 8% Neuropathies (e.g. Diabetic Neuropathy, Peripheral Neuropathy) Small Nerve Fiber Degeneration PSYCHOLOGICAL Mood Emotional vitality 1 0 2%31% \*Source: Based on Niagen® NR trials registered on clinicaltrials.gov. Used ChromaDex classification into intrinsic capacity domains. As of February 23, 2023. Chart includes suspended trials but does not include pharmacokinetic or terminated trials. \*\*Based on Niagen® nicotinamide riboside (NR) clinical trials listed on clinicaltrials.gov Anxiety Depression

------

![](cdxcearningspresentation027.jpg)

27 Contact Info Tom Shumaker LifeSci Advisors, Managing Director T: +1.917.929.7600 TShumaker@lifesciadvisors.com www.chromadex.com Where to buy TRU NIAGEN® truniagen.com amazon.com

------